Home / Stocks / Sudeep Pharma Limited
SUDEEPPHRM

Sudeep Pharma Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,212.1

Change

+9.9 (0.82%)

Open

₹1,208.2

Prev. Close

₹1,202.2

Day High

₹1,238.7

Day Low

₹1,112.4

Volume Analysis

Traded

957,390

Delivered

99,221

Delivery %

10.36%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (25.2%)
  • •Strong operating margin (35.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (27.3%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,389.36 ₹1,314.03 ₹1,263.06 ₹1,187.73 ₹1,136.76 ₹1,061.43 ₹1,010.46
Fibonacci ₹1,314.03 ₹1,265.78 ₹1,235.98 ₹1,187.73 ₹1,139.48 ₹1,109.68 ₹1,061.43
Camarilla ₹1,246.83 ₹1,235.26 ₹1,223.68 ₹1,187.73 ₹1,200.52 ₹1,188.95 ₹1,177.37

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+102.51%

1 Week

+0.55%

1 Month

+24.75%

3 Months

+9.02%

6 Months

+80.01%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹170.91

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

17.76%

Net margin 26.62% × asset turnover 0.48x × equity multiplier 1.39x

Company Overview

Sector

Healthcare

Market Cap

₹13,545 Cr

P/E (TTM)

71.9

ROE

25.2%

Book Value

₹84.8

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Sudeep Pharma Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (25.2%); strong operating margin (35.0%). Strong 3-year EPS growth (27.3%).

TopFund Score — Fundamentals Quality

65/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

93

Valuation

0

Cash Flow

14

Corporate Governance

54

Momentum

79

Institutional Ownership

42

Business Quality

100

Risk & Volatility

62

Liquidity

50

From Screener.in

  • +Company has delivered good profit growth of 39.0% CAGR over last 5 years
  • +Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%
  • −Stock is trading at 14.2 times its book value

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Submission of Transcript for the Earnings call held on 29.10.2026

Audio recording of the 29 October 2026 earnings call uploaded.

Submission of Newspaper Advertisement for unaudited Financials for the Quarter and Half Year ended 30th September 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 149 116 158 125 163 172 182 158 197
Expenses + 85 76 99 81 107 112 120 103 123
Operating Profit 63 39 59 44 55 60 63 55 73
OPM % 43.0% 34.0% 37.0% 35.0% 34.0% 35.0% 34.0% 35.0% 37.0%
Other Income + 2 2 4 5 10 7 6 5 6
Interest 1 1 2 2 2 1 2 2 3
Depreciation 3 3 3 3 4 4 4 4 5
Profit before tax 62 38 58 44 60 62 63 54 71
Tax % 21.0% 24.0% 24.0% 29.0% 21.0% 23.0% 23.0% 25.0% 27.0%
Net Profit + 49 29 44 31 47 48 49 41 52
EPS in Rs 6 3 5 3 5 4 4 4 5
Raw PDF — — — — — — — — —
YoY Sales growth — — — — 9 49 16 27 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 123 215 343 429 459 502 642 710
Expenses + 98 171 276 338 276 310 419 459
Operating Profit 25 44 67 90 183 192 223 251
OPM % 21.0% 20.0% 20.0% 21.0% 40.0% 38.0% 35.0% 35.0%
Other Income + 3 3 7 9 6 9 28 25
Interest 1 1 2 6 5 7 8 8
Depreciation 3 4 5 8 9 11 15 17
Profit before tax 25 43 69 86 175 183 228 250
Tax % 27.0% 22.0% 27.0% 28.0% 24.0% 24.0% 24.0% —
Net Profit + 18 33 50 62 133 139 174 189
EPS in Rs 2 4 6 7 16 14 15 17
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — 75 59 25 7 9 28 27

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 80 113 162 222 355 481 872 946
Borrowings + 20 31 84 83 78 140 150 189
Other Liabilities + 30 67 97 113 80 86 141 182
Total Liabilities 131 213 344 420 514 717 1,174 1,329
Fixed Assets + 60 68 137 158 180 189 337 524
CWIP 8 24 8 26 45 88 185 54
Investments 6 19 0 3 0 0 0 0
Other Assets + 57 102 199 232 289 439 652 751
Total Assets 131 213 344 420 514 717 1,174 1,329
Equity Capital 1 1 1 1 1 10 11 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 10 35 -3 48 66 49 70
Cash from Investing Activity + -22 -40 -38 -50 -49 -79 -327
Cash from Financing Activity + 12 13 51 -10 -13 53 247
Net Cash Flow 0 8 10 -11 4 23 -10
Free Cash Flow 1 24 -77 1 13 -15 -49
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 62 104 22 78 60 47 56

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 76.16% → 76.16%
  Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 4.57% 4.18% 6.39% 6.87%
Promoters 76.16% 76.16% 76.16% 76.16%
FII 1.67% 1.55% 1.81% 2.93%
DII 17.59% 18.11% 15.64% 14.06%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sudeep Pharma Limited (this stock) 13,545 71.9 14.14 25.2%
Marksans Pharma Limited 13,347 23.8 4.0 15.2%
Corona Remedies Limited 14,010 63.6 17.34 29.5%
Rainbow Childrens Med Ltd 12,607 43.0 7.34 16.7%
Vijaya Diagnostic Cen Ltd 14,524 71.3 13.69 18.9%
Jubilant Pharmova Ltd 14,883 50.4 2.08 6.53%
Concord Biotech Limited 12,146 42.6 5.86 12.9%

Which Mutual Funds Hold Sudeep Pharma Limited?

Frequently Asked Questions about Sudeep Pharma Limited

Community Sentiment

What are other investors saying about Sudeep Pharma Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.